Takeda announces late-breaking data from phase 2b study of tak-279, an investigational, oral, once-daily tyk2 inhibitor, in patients with active psoriatic arthritis at american college of rheumatology convergence annual meeting

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the company will present positive results from its randomized, double-blind, placebo-controlled, phase 2b trial evaluating tak-279, an investigational oral allosteric tyrosine kinase 2 (tyk2) inhibitor with next generation selectivity, in patients with active psoriatic arthritis. these data (abstract #l12) will be presented on tuesday, november 14 as part of the late-breaking poster session from 9:.
TAK Ratings Summary
TAK Quant Ranking